Faculty Profile

 


Catriona Jamieson, M.D., Ph.D.
Dr. Jamieson

Catriona Jamieson, M.D., Ph.D.

Associate Professor of Medicine

Division of Hematology-Oncology
Director for Stem Cell Research,
UCSD Moore Cancer Center


Office Address:

Division of Hematology-Oncology

University of California, San Diego

Moores Cancer Center, MC-0987

3855 Health Sciences Drive

La Jolla, CA 92093

 

cjamieson@ucsd.edu
Office: ( 858) 534-7128
FAX:  (858) 822-5399

Education and Training

BS Biology-Genetics, University of British Columbia 1987
Ph.D. Microbiology, University of British Columbia 1992
MD University of British Columbia 1995
Resident University of British Columbia 1995-1998
Fellow, Bone Marrow Transplant

University of British Columbia

1998
Fellow, Bone Marrow Transplant

Stanford University

1999-2002
Postdoctoral Research Fellow

Stanford University

2002-2005

 

Research Interests

Dr. Jamieson specialized in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies. In the past two years, Dr. Jamieson’s stem-cell research studies have taken a great leap: from identifying a promising treatment in the laboratory to opening and completing the first clinical trial to target cancer stem cells in humans. This trial is the result of teamwork that has brought together her discoveries in myeloproliferative neoplasms and a local pharmaceutical company’s drug development track.

 

Publications

Jamieson CHM. Angiogenesis in hematologic malignancies: biology and pathogenetic mechanisms. Mdvista Journal of Medicine (serial online) November. Available at: http://www.mdvista.com. (November 2000)

Jamieson CHM. Antiangiogenic therapy in hematologic malignancies: potential role in multiple myeloma, myelodysplastic syndromes and acute myelogenous leukemia. Mdvista Journal of Medicine (serial online) November. Available at: http://www.mdvista.com. (November 2000)

Jamieson CHM, Amylon M, Wong R, Blume KG. Allogeneic hematopoietic cell transplantation for patients with high risk acute lymphoblastic leukemia in first or second complete remission using fractionated total body irradiation and high dose etoposide: a 15 year experience. Experimental Hematology 2003;31: 981-986.

Jamieson CHM, Weissman IL, Passegue E. Chronic versus acute myelogenous leukemia: A question of self-renewal. Cancer Cell 2004;6(6):531-533.

Jamieson CH, Ailles LE, Dylla S, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Manz M, Li K, Keating A, Sawyers C, Weissman IL. Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML. The New England Journal of Medicine 2004;351:657-667.

Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebel J, Decesare S, Jovin T, Zafonte R, Lebowitz J, Flickinger JC, Tong D, Marks MP, Jamieson C, Luu D, Bell-Stephens T, Teraoka J. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. Journal of Neurosurgery 2005;103:38-45.

Jamieson CHM, Gotlib J, Durocher JA, Chao MP, Rajan Mariappan M, Lay M, Jones C, Zehnder JL, Lillberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. PNAS 2006;103(16):6224-6229.

Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-9344.

Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008;132:681-696.

Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008;13:321-330.

Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26(17): 2911-5.

Minami Y, Stuart S, Ikawa, T, Akihiro, A, Naoe, T, Jamieson, C, Wang, J. Transformation of E2A-deficient pluripotent progenitors by BCR-ABL generates imatnib-resistant leukemic stem cells. Proc Natl Acad Sci, USA 2008;105:17967-17972.

Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CH, Wang JY, Naoe T. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol. 2008;88:471-475. PMC2626150.

Cross NCP, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval J-L, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008;22:1975-1989.

Jamieson CHM, Barroga CF, Vainchenker WP. Miscreant myeloproliferative disorder stem cells, Leukemia 2008;22:2011-2019.

Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008;2008:436-442.

Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, Vanarsdale T, Beachy PA, Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776-779.

Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009;23:1708-1715.

Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. [2010 Feb 1 Epub ahead of print]

Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CA. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010;20(2):111-21. Epub 2010 Jan 18.

Goff D, Jamieson C. Cycling Toward Elimination of Leukemic Stem Cells. Cell Stem Cell. 2010; 296-297.

Jamieson C. Split ends in CML: divergent roles of Hes1. Blood. 2010 Apr 8;115(14):2726.

Jamieson CH, O’Brien C, Kreso A. Cancer Stem Cells and Self-renewal. AACR. Clin Cancer Res. 2010 Jun 15;16(12):3113-20. Epub 2010 Jun 8.

Rice KN, Jamieson CH. Molecular pathways to CML stem cells. Int J Hematol. 2010 Jun;91(5):748-52. Epub 2010 Jun 10.

Jamieson CH, O’Brien C, Kreso A. Cancer Stem Cells and Self-renewal. AACR Clinical Cancer Research. Clin Cancer Res. 2010 Jun 15;16(12):3113-20. Epub 2010 Jun 8.

Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010 Jul 1;120(7):2254-64.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 1;29(7):789-96. Epub 2011 Jan 10. PMID: 21220608

Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28;9:185. PMID: 22035283

Crews LA, Jamieson CH. Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep. 2012 Jun;7(2):125-32. PMID: 22467334

Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012;7(6):e39725. Epub 2012 Jun 29.

Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT. Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2012 Aug 14;22(2):209-21.

Crews LA, Jamieson CH. Selective elimination of leukemia stem cells: Hitting a moving target. Cancer Lett. 2012 Aug 17. [Epub ahead of print]

Newton IG, Plaisted WC, Messina-Graham S, Abrahamsson Schairer AE, Shih AY, Snyder EY, Jamieson CH, Mattrey RF. Optical imaging of progenitor cell homing to patient-derived tumors. Contrast Media Mol Imaging. 2012 Nov;7(6):525-36. doi: 10.1002/cmmi.1485.

Daniel Goff, Angela Court-Recart, Alice Shih, Anil Sadarangani, Christian Barrett, Hye-Jung Chun, Maryla Krajewska, Heather Leu, Jun Wei, Dayong Zhai, Ifat Geron, Qingfei Jiang, Ryan Chuang, Larisa Balaian, Jason Gotlib, Mark Minden, Giovanni Martinelli, Annelie Schairer, Wenxue Ma, Jessica Rusert, Dr. Kim-Hien Dao, Kamran Shazand, John McPherson, Peggy Wentworth, Christina Jamieson, Sheldon Morris, Lawrence Goldstein, Thomas Hudson, Marco Marra, Dr. Kelly Frazer, Kristen Smith, Dr. Maurizio Pellecchia, John Reed, Catriona H.M. Jamieson. Cycling Toward Leukemia Stem Cell Elimination with a Selective Sonic Hedgehog Antagonist Submitted.

Alice Shih, Annelie Schairer, Hye-Jung Chun, Christian Barrett, Angela Court-Recart, Daniel Goff, Larisa Balaian, Eva Hellqvist, Sacha Prashad, Ifat Geron, Dr. Amy Jackson-Fisher, Jerry Wu, Qingfei Jiang, Jason Gotlib, Mark Minden, Heather Leu, Russell Wall, Wenxue Ma, Kamran Shazand, John McPherson, Steven M Kornblau, Anna-Lisa Prabhu, Andrew Mungall, Richard Moore, Melissa McMahon, Lars Engstrom, Peter Wells, Zhou Zou, Dr. Michael Munchhof, Dr. Ida Deichaite, Dr. Minya Pu, Dr. Lei Bao, Prof. Giovanni Martinelli, Dr. Jorge Cortes, Dr. Tannishtha Reya, Sheldon Morris, Prof. Karen Messer, Dr. Hanna Mikkola, Dr. Wendy Levin, Dr. Todd VanArsdale, Dr. Thomas Hudson, Marco Marra, Dr. Kelly Frazer, Dr. Anil Sadarangani, Catriona H.M. Jamieson. Cycling Toward Leukemia Stem Cell Elimination with a Selective Sonic Hedgehog Antagonist. Submitted.

Qingfei Jiang, Leslie A. Crews, Christian L. Barrett, Hye-Jung Chun, Angela C. Court, Daniel J. Goff, Mark Minden, Anil Sadarangani, Jessica M. Rusert, Kim-Hien T. Dao, Sheldon R. Morris, Lawrence S. Goldstein, Marco A. Marra, Kelly A. Frazer, and Catriona H. M. Jamieson. ADAR1, an RNA Editase, Promotes Malignant Progenitor Reprogramming in Chronic Myeloid Leukemia. Submitted.

Kristen M. Smith and Catriona H. M. Jamieson. Therapeutics against cancer stem cells: Targeting the root of cancer. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Accepted.

Takaomi Sanda, Jeffrey W. Tyner, Alejandro Gutierrez, Vu N. Ngo, Jason Glover, Bill H. Chang, Andrew Weng, Wenxue Ma, Jessica Tatarek, Angela G. Fleischman, Yebin Ahn, Yandan Yang, Wenjun Zhou, Maria Kleppe, Ross Levine, Donna S. Neuberg, Richard Moriggl, Mathias Muller, Michelle A. Kelliher, Catriona H. M. Jamieson, Nathanael S. Gray, Louis M. Staudt, Brian J. Druker, and A. Thomas Look. TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia. Submitted to Nature.

Laboratory

Laboratory Personnel
Name Title Laboratory Focus
Alice Shih SRA Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Angela Court SRA Derivation and Characterization of Myeloproliferative Disorder Stem Cells
Anil Sadarangani Team Leader Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Catriona Jamieson PI Mechanisms of lineage priming in MPDs.
Cayla Mason SRA Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Eva Hellqvist Postdoc Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Fay Jiang Postdoc Derivation and Characterization of Myeloproliferative Disorder Stem Cells
Gabriel Pineda Postdoc Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Heather Leu SRA Preclinical Development of a pan Bcl2 Inhibitor for Cancer Stem Cell-Directed Therapy
Janine Low Postdoc Preclinical Development of a pan Bcl2 Inhibitor for Cancer Stem Cell-Directed Therapy
Jane Isquith Grad Student Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Katie Kane SRA Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Kim Wilson SRA Lab Administrator
Larisa Balaian Project Scientist Derivation and Characterization of Myeloproliferative Disorder Stem Cells
Leslie Crews Robertson Project Scientist Derivation and Characterization of Myeloproliferative Disorder Stem Cells
Lily Earnest Undergrad Student Undergraduate Student Intern
Marianna Zipeto Grad Student Derivation and Characterization of Myeloproliferative Disorder Stem Cells
Rusty Wall

SRA

Clinical Trial Coordinator
Tina Wu Project Scientist Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Wenxue Ma Project Scientist Preclinical Development of a oan Bcl2 Inhibitor for Cancer Stem Cell-Directed Therapy